Pdr Hospital Library 2002 - Couverture rigide

Couverture rigide

ISBN 10 : 1563634112 ISBN 13 : 9781563634116

Editeur : Medical Economics Company, 2002

Synopsis

Book by None

A propos du livre

Quatrième de couverture

Completely revised and updated, the 2002 PDR provides FDA–approved drug information on more than 4,000 prescription drugs (brand and generic names), over 2,000 full–color, actual–size photos of medicines for instant identification, and important data on over 250 drug manufacturers. New medicines, new drug interaction data, the most recent side effects findings, and certain drugs now removed from the market make it absolutely critical that medical and healthcare professionals keep up–to–date with the very latest prescription drug information. The 2002 PDR contains: the newest drugs–which drugs are indicated for the diagnosed condition; how different drugs interact; latest findings on side effects caused by the prescribed drug; recommended dosages; clinical pharmacology; pediatric use; contraindications; FDA use–in–pregnancy ratings; and more. Among the new drugs featured in this edition are: Nexium (esomeprazole magnesium), a new proton pump inhibitor approved for the treatment of GERD and H. pylori eradication; Canasa (mesalamine), a new anti–inflammatory rectal suppository indicated for the treatment of active ulcerative proctitis; Lumigan (bimatoprost), a new ophthalmic solution approved for the reduction of elevated intraocular pressure associated with open angle glaucoma or ocular hypertension; Advair (fluticasone propionate/salmeterol xinafoate), a new combination inhalation powder approved for the maintenance treatment of asthma; Trizivir (abacavir sulfate/lamivudine/zidovudine), a new combination nucleoside analogue approved for the treatment of HIV–1 infection; Cancidas (caspofungin acetate), the first of a new class of antifungal agents called glucan synthesis inhibitors, is indicated for refractory treatment of invasive aspergillosis; Remeron SolTab (mirtazapine), a new orally disintegrating tablet for the treatment of depression; Lunelle Monthly (medroxyprogesterone acetate/estradiol cypionate), a new long acting contraceptive injection; Gleevec (imatinib mesylate), a new oral protein–tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML); and Valcyte (valganciclovir HCl), the new antiviral prodrug of ganciclovir, is indicated for CMV retinitis in patients with AIDS. New larger trim size allows dramatically improved readability.

Présentation de l'éditeur

New medicines, new drug interaction data, the most recent side effects findings, and certain drugs now removed from the market make it absolutely critical that the physician keeps up–to–date with the very latest prescription drug information.

Not only are today′s prescription drugs vital to the patient′s well–being, but their effectiveness and safety can impact the integrity and security of all involved healthcare professionals as well.

In today′s fast–moving healthcare field, it is vital that the physician keeps abreast of:

∗The latest drugs – which drugs are indicated for the diagnosed conditions

∗How different drugs interact

∗Latest findings on side effects caused by the prescribed drug

∗Recommended dosages

∗Clinical pharmacology

∗Paediatric use

∗Contraindications

∗FDA use–in–pregnancy ratings

∗And much, much more...

Now available in its 56th edition the 2002 PDR® provides the most complete data on over 4,000 drugs by brand and generic name (both in the same convenient index), manufacturer and product category. It guarantees the physician the security and safety of having up–to–the–minute FDA–approved information on over 4,000 prescription drugs and important data on over 250 drug manufacturers.

Détails de l'édition

• Éditeur: Medical Economics Company
• Date d'édition: 2002
• Langue: anglais
• ISBN 10: 1563634112
• ISBN 13: 9781563634116
• Reliure: Relié
• Nombre de pages: 3000
• Coordonnées du fabricant: non disponible
• Personne responsable: non disponible